AU2008314048B2 - Novel patient subgroups for thrombolysis - Google Patents

Novel patient subgroups for thrombolysis Download PDF

Info

Publication number
AU2008314048B2
AU2008314048B2 AU2008314048A AU2008314048A AU2008314048B2 AU 2008314048 B2 AU2008314048 B2 AU 2008314048B2 AU 2008314048 A AU2008314048 A AU 2008314048A AU 2008314048 A AU2008314048 A AU 2008314048A AU 2008314048 B2 AU2008314048 B2 AU 2008314048B2
Authority
AU
Australia
Prior art keywords
patient
stroke
patients
timi
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008314048A
Other languages
English (en)
Other versions
AU2008314048A1 (en
Inventor
Yasir Alaa Shafeek Al-Rawi
Alice Ebel
Mariola Sohngen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008314048(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07020401A external-priority patent/EP2050462A1/en
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2008314048A1 publication Critical patent/AU2008314048A1/en
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S Request for Assignment Assignors: PAION DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU2008314048B2 publication Critical patent/AU2008314048B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2008314048A 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis Ceased AU2008314048B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07020401.1 2007-10-18
EP07020401A EP2050462A1 (en) 2007-10-18 2007-10-18 Improved treatment of stroke patients
EP07022867.1 2007-11-26
EP07022867 2007-11-26
EP08017954 2008-10-15
EP08017954.2 2008-10-15
PCT/EP2008/008871 WO2009049914A2 (en) 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis

Publications (2)

Publication Number Publication Date
AU2008314048A1 AU2008314048A1 (en) 2009-04-23
AU2008314048B2 true AU2008314048B2 (en) 2013-07-25

Family

ID=40567844

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008314048A Ceased AU2008314048B2 (en) 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis

Country Status (28)

Country Link
US (2) US20100272704A1 (cg-RX-API-DMAC7.html)
EP (1) EP2211898B1 (cg-RX-API-DMAC7.html)
JP (2) JP5509085B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100089077A (cg-RX-API-DMAC7.html)
CN (1) CN101903039B (cg-RX-API-DMAC7.html)
AR (1) AR068914A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008314048B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0817785A2 (cg-RX-API-DMAC7.html)
CA (1) CA2702378A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009000752A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118417T1 (cg-RX-API-DMAC7.html)
DK (1) DK2211898T3 (cg-RX-API-DMAC7.html)
EA (1) EA020776B1 (cg-RX-API-DMAC7.html)
ES (1) ES2611155T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170001T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032867T2 (cg-RX-API-DMAC7.html)
IL (1) IL205175A0 (cg-RX-API-DMAC7.html)
LT (1) LT2211898T (cg-RX-API-DMAC7.html)
MX (1) MX2010004157A (cg-RX-API-DMAC7.html)
MY (1) MY159200A (cg-RX-API-DMAC7.html)
NZ (1) NZ584640A (cg-RX-API-DMAC7.html)
PL (1) PL2211898T3 (cg-RX-API-DMAC7.html)
PT (1) PT2211898T (cg-RX-API-DMAC7.html)
RS (1) RS55590B1 (cg-RX-API-DMAC7.html)
SI (1) SI2211898T1 (cg-RX-API-DMAC7.html)
TW (1) TWI482628B (cg-RX-API-DMAC7.html)
WO (1) WO2009049914A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002548B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
CA2107476C (en) * 1991-04-16 2007-12-18 Martin Ulrich Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
DE59307091D1 (de) * 1992-12-04 1997-09-11 Schering Ag Thrombininhibitor aus speichel von protostomiern
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6354999B1 (en) * 2000-01-14 2002-03-12 Florence Medical Ltd. System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
KR20060015721A (ko) * 2003-05-05 2006-02-20 파이온 도이치란트 게엠베하 신경보호제로서의 글루타메이트 수용체 길항제
US20050085478A1 (en) * 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAULAZ A. et al., "Selecting Patients for Early Stroke Treatment with Penumbra Images", Cerebrovascular Diseases, 2005, Vol. 20, Suppl. 12, pages 19-24 *

Also Published As

Publication number Publication date
EP2211898B1 (en) 2016-12-07
IL205175A0 (en) 2010-11-30
JP2014065739A (ja) 2014-04-17
EP2211898A2 (en) 2010-08-04
CN101903039A (zh) 2010-12-01
AU2008314048A1 (en) 2009-04-23
CL2009000752A1 (es) 2009-12-04
HRP20170001T1 (hr) 2017-02-24
CN101903039B (zh) 2014-04-02
MY159200A (en) 2016-12-30
US20140314736A1 (en) 2014-10-23
HUE032867T2 (en) 2017-11-28
PL2211898T3 (pl) 2017-03-31
MX2010004157A (es) 2010-04-30
PT2211898T (pt) 2017-01-31
SI2211898T1 (sl) 2017-02-28
JP5509085B2 (ja) 2014-06-04
EA201070485A1 (ru) 2010-10-29
KR20100089077A (ko) 2010-08-11
BRPI0817785A2 (pt) 2015-03-24
ZA201002548B (en) 2011-06-29
DK2211898T3 (en) 2017-01-30
ES2611155T3 (es) 2017-05-05
WO2009049914A2 (en) 2009-04-23
EA020776B1 (ru) 2015-01-30
AR068914A1 (es) 2009-12-16
JP2011500617A (ja) 2011-01-06
CA2702378A1 (en) 2009-04-23
TWI482628B (zh) 2015-05-01
TW200927164A (en) 2009-07-01
HK1151233A1 (en) 2012-01-27
US20100272704A1 (en) 2010-10-28
NZ584640A (en) 2012-10-26
WO2009049914A3 (en) 2009-08-06
CY1118417T1 (el) 2017-06-28
LT2211898T (lt) 2017-01-25
RS55590B1 (sr) 2017-06-30

Similar Documents

Publication Publication Date Title
Furlan et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial
Shin et al. Retrospective analysis of a 10-year experience of stereotactic radiosurgery for arteriovenous malformations in children and adolescents
Urbach et al. Local intra-arterial fibrinolysis in thromboembolic “T” occlusions of the internal carotid artery
Wu et al. Assessing the clinical efficacy of recombinant tissue plasminogen activator on acute cerebral infarction
EP2050462A1 (en) Improved treatment of stroke patients
Zhu et al. Safety and efficacy of intravenous tirofiban infusion after mechanical thrombectomy in acute ischemic stroke: a retrospective observational study
EP2211898B1 (en) Novel patient subgroups for thrombolysis
Xianxian et al. The efficiency analysis of thrombolytic rt-PA combined with intravascular interventional therapy in patients with acute basilar artery occlusion
D'Aliberti et al. Ischemic stroke
JP2011500617A5 (cg-RX-API-DMAC7.html)
Moreno-Gomez et al. Therapeutic options for disabling acute ischemic stroke
HK1151233B (en) Novel patient subgroups for thrombolysis
Massimi et al. Cavernomas
Connors 3rd Interventional stroke therapy: the potential benefit of direct intra-arterial infusion.
Venketasubramanian et al. Brain attack: needing resuscitation
Yin Acute basilar artery occlusion
Oguro et al. Effect of one-shot intravenous 0.42 mega unit urokinase therapy in patients with acute ischemic stroke
Polhemus et al. Tandem Occlusion to Thrombolysis in Cerebral Infarction (TICI) 3: A Case of Perioperative Tirofiban for Carotid Artery Stenting
Machraoui et al. Efficacy and safety of APSAC in the treatment of acute myocardial infarction
Suri Thrombolysis in Acute Ischemic Stroke
Goldstein Medical therapy for acute ischemic stroke
Wong et al. Acute ischaemic stroke: management, recent advances and controversies
Schellinger Stroke management in the early phase
Csiba et al. Fibrin-degrading drugs in acute stroke
Arnold et al. Intraarterial thrombolysis and the role of intensive care in acute ischaemic stroke

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: H. LUNDBECK A/S

Free format text: FORMER APPLICANT(S): PAION DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired